

**UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK**

In re:

PURDUE PHARMA L.P., *et al.*,¹

Debtors.

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered)

NOTICE OF PROFESSIONAL FEE HOURLY RATES

PLEASE TAKE NOTICE that effective July 1, 2020, the hourly rates of Province, Inc., financial advisor to the Official Committee of Unsecured Creditors of Purdue Pharma L.P., *et al.*, are to be modified as follows:

	Rates July 1, 2019 – June 30, 2020	Rates July 1, 2020 – June 30, 2021
Principal	\$800-935	\$880-975
Managing Director	\$660-720	\$670-790
Senior Director	\$580-640	\$600-670
Director	\$500-570	\$550-600
Vice President	-	\$510-550
Senior Associate	\$400-490	\$430-540
Associate	\$350-400	\$360-430
Analyst	\$230-350	\$240-360
Para Professional	\$175	\$185

¹The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF L.P. (0495), SVC Pharma L.P. (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

Date: June 15, 2020

PROVINCE, INC.

/s/ Michael Atkinson

Michael Atkinson, Principal

2360 Corporate Circle, Suite 330

Henderson, NV 89074

(702) 685-5555; Fax: (702) 685-5556

*Financial Advisor to the Official Committee
of Unsecured Creditors of Purdue Pharma
L.P., et al.*